Latest News
An updated drug shows promise in treating traumatic brain injuries that can lead to neurodegenerative diseases.
A team of researchers including Alzheimer’s Disease Research grantee Eunhee Kim, PhD, have used a 3D brain cell culture model to show that the exercise-induced muscle hormone, irisin, reduces the level of amyloid beta associated with Alzheimer’s disease.
A new study bridging neuroscience and machine learning offers insights into the potential role of astrocytes in the human brain.
A BrightFocus-funded team has identified a potential way to diagnose a rare but devastating form of early Alzheimer’s disease by examining cells of the inner eye.
Global nonprofit BrightFocus Foundation is pleased to announce that it has received a $50,000 donation from Alzheimer’s Los Angeles (Alzheimer’s LA) to support two innovative Alzheimer’s disease research scientists as part of the Foundation’s 2023 research portfolio.
The U.S. Food and Drug Administration today granted full approved of Leqembi (lecanemab-irmb) for the treatment of Alzheimer’s disease based on its ability to clear toxic amyloid from the brain.
In this Issue
- President’s Corner
- New Blood Test Detects Unique Biomarker for Alzheimer’s
- Researcher Spotlight: Kevin Beier, PhD
- Medications That Can Mimic Dementia
- Help Fight Alzheimer’s Through a Donor Advised Fund
In a finding that raises new questions about the connection between amyloid plaques and Alzheimer’s disease, a Dutch study showed people over age 100 maintained sharp minds despite having brain changes associated with dementia.
The FDA has approved the use of atypical antipsychotic drug Rexulti (brexpiprazole) for treating agitation associated with Alzheimer’s dementia, making it the first FDA-approved treatment for Alzheimer’s agitation in the U.S.
BrightFocus honors the life of Donald L. Price, MD.
